Overview

A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

Status:
NOT_YET_RECRUITING
Trial end date:
2033-02-11
Target enrollment:
Participant gender:
Summary
This study will assess long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with Atopic Dermatitis (AD) who participated in previous afimkibart clinical trials.
Phase:
PHASE2
Details
Lead Sponsor:
Hoffmann-La Roche